Figure (Logo)
Mounjaro Injection, Solution
Product Images NDC 0002-1243
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Mounjaro (NDC 0002-1243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Package Label (Mounjaro™, 10 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Packaging label for Mounjaro 10 mg/0.5 mL (tirzepatide) injection, a subcutaneous solution by Eli Lilly and Company. The label indicates a carton containing 4 single-dose prefilled pens. Key details include the strength 10 mg/0.5 mL prominently displayed in magenta with an image of a prefilled pen and instructions for weekly use. The label features the Mounjaro logo and the note 'Prescription only.'*
Package Label (Mounjaro™, 12.5 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Packaging label for Mounjaro (tirzepatide) injection 12.5 mg/0.5 mL by Eli Lilly and Company. The label includes product name, strength, dosage form as injection, and indicates the package contains four 12.5 mg/0.5 mL single-dose prefilled pens for subcutaneous use. The design uses blue and white colors with the Mounjaro logo and an image of the prefilled pen.*
Package Label (Mounjaro™, 15 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Packaging label for Mounjaro (tirzepatide) injection 15 mg/0.5 mL by Eli Lilly and Company. The carton holds 4 single-dose prefilled pens for subcutaneous use. The label includes the product name, strength, dosage form, number of prefilled pens, NDC, and instructions to use one pen every week. A product image of a prefilled pen is shown.*
Package Label (Mounjaro™, 2.5 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Packaging label for Mounjaro (tirzepatide) injection, 2.5 mg/0.5 mL subcutaneous solution by Eli Lilly and Company. The label indicates a pack of 4 single-dose prefilled pens. The front panel displays the product name, strength, dosage form, and an image of a prefilled pen.*
Package Label (Mounjaro™, 5 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Packaging label for Mounjaro (tirzepatide) injection 5 mg/0.5 mL by Eli Lilly and Company. The label shows a white and purple box containing 4 single-dose prefilled pens for subcutaneous injection. The label includes dosage strength, quantity, and usage instructions.*
Package Label (Mounjaro™, 7.5 mg/0.5 mL, Carton, 4 Single-Dose Pens)
Mounjaro 7.5 mg/0.5 mL (tirzepatide) injection carton for subcutaneous use by Eli Lilly and Company. Box contains 4 single-dose prefilled pens. Label shows product name, strength, dosage form, usage instructions, barcode, and image of the prefilled pen with a purple cap and green labeling.*
Figure (Moun Ifu 1 V1)
Mounjaro injection pen device in a white and gray body with a purple cap. It is a subcutaneous injectable solution product of tirzepatide by Eli Lilly and Company. The device likely corresponds to one of the available strengths for Mounjaro provided in the label set.*
Figure (Moun Ifu 10 V1)
An instructional diagram focusing on the lower part of a syringe or injection device, specifically identifying the gray plunger component used for administering the medication.*
Figure (Moun Ifu 2 V1)
An instructional diagram of a tirzepatide injection pen showing labeled parts including the purple injection button at the top, lock ring, an indicator, lock or unlock mechanism, the medicine reservoir inside the pen, a clear base, and a gray base cap at the bottom and needle end. The orientation with top and bottom is indicated.*
Figure (Moun Ifu 3 V1)
An illustration showing an injection pen labeled with an arrow and text indicating the location of the expiration date on the pen. The injection pen is consistent with the dosage form for Mounjaro (tirzepatide) injection, solution for subcutaneous use.*
Figure (Moun Ifu 4a V1)
An illustration showing the recommended subcutaneous injection sites for Mounjaro (tirzepatide). The highlighted injection areas are the abdomen around the navel and the front and outer sides of both thighs, indicating preferred locations for administering the injection solution.*
Figure (Moun Ifu 4b V1)
An anatomical illustration showing a rear view of a human figure with highlighted areas in purple on the outer upper arms, indicating recommended subcutaneous injection sites for the medication.*
Figure (Moun Ifu 5 V1)
An instructional illustration showing a hand holding a Mounjaro tirzepatide injection pen with a locked symbol highlighted on the pen. The diagram indicates removing the gray base cap by pulling downward from the clear base of the pen device. The labels identify the clear base and gray base cap parts of the injection pen.*
Figure (Moun Ifu 6 V1)
An instructional illustration showing how to administer Mounjaro (tirzepatide) injection subcutaneously. The image depicts a person holding an injection pen near their abdomen, preparing for a subcutaneous injection.*
Figure (Moun Ifu 7 V1)
An instructional illustration showing a hand holding a Mounjaro injection pen, highlighting a rotational motion of the dial or button with an arrow. The image indicates the step to unlock or prepare the injection device for subcutaneous administration.*
Figure (Moun Ifu 8 V1)
Illustration showing a hand administering a subcutaneous injection into the abdominal area using a syringe device, consistent with the injection route for Mounjaro (tirzepatide) solution.*
Figure (Moun Ifu 9 V1)
An illustration showing a close-up of a gray plunger inside a transparent syringe or injection device, indicating the component labeled as 'Gray Plunger'.*
Figure (Moun Qr)
Structural Formula (Moun Uspi Chem Struc)
Chemical structure of tirzepatide, showing its peptide chain with amino acid sequence and attached molecular groups, as provided in the product data for Mounjaro (tirzepatide).*
Figure 1 (Moun Uspi F1 V1)
A line graph depicting insulin levels (mIU/L) over time (minutes) comparing tirzepatide 15 mg and placebo at baseline and week 28. The graph shows measurements divided into 1st and 2nd phases, with tirzepatide 15 mg at week 28 displaying a notable rise in insulin levels reaching approximately 225 mIU/L at 120 minutes, contrasting with relatively stable lower levels for placebo and baseline groups.*
Figure 2 (Moun Uspi F2 V1)
A line graph comparing HbA1c percentage over 40 weeks post randomization for Mounjaro injection at doses of 5 mg, 10 mg, and 15 mg versus Semaglutide 1 mg. The x-axis shows weeks post randomization and the y-axis shows HbA1c percentage. All Mounjaro doses show a decrease in HbA1c over time, with values slightly lower than Semaglutide at week 40.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
